Nachrichten zur Atea ASA Aktie

Atea ASA - share buyback

Oslo, 30 October Please see below information about transactions made under the share buyback programme for Atea ASA. Date on which the…

Presentation of 3[rd] quarter 2024 results

Atea ASA will present its 3[rd] quarter 2024 financial results on Wednesday, 23 October 2024 at 08:00 CEST. The presentation will…

Atea Share Savings Program – notification of trade

Reference is made to the stock exchange notice dated June 6, 2023 regarding the launch and terms of the Atea…

Presentation of 2[nd] quarter 2024 results

Atea ASA will present its 2[nd] quarter 2024 financial results on Friday, 12 July 2024 at 08:00 CEST. The presentation will…

Atea earns platinum-level sustainability award for fifth consecutive year

For the fifth consecutive year, Atea ASA has earned the highest (“platinum”) rating in environmental and social performance by EcoVadis,…

Ex dividend NOK 3.50 today

The shares in Atea ASA will be traded ex dividend NOK 3.50 as from today, 22 May 2024. For further information, please…

Atea Share Savings Program – notification of trade

Reference is made to the stock exchange notice dated June 6, 2023 regarding the launch and terms of the Atea…

Mandatory notification of trade

On April 26, the following transactions took place in Atea ASA (the Company): 1. Exercise of stock options Employees of the Atea…

Presentation of 1[st] quarter 2024 results

Atea ASA will present its 1[st] quarter 2024 financial results on Thursday, 25 April 2024 at 08:00 CEST. The presentation will…

Grant of share options to primary insiders in Atea ASA

On 8 April 2024, key employees in the Atea Group were granted share options in Atea ASA. The following primary insiders…

Key information relating to cash dividend to be paid by Atea ASA

The Board of Atea ASA has proposed cash dividend with two payments, and with following key details: Dividend amount:     …

Atea ASA 2023 Annual Report in ESEF format

The company publishes its annual financial statements in European Single Electronic Format (ESEF), available as an attachment to this release. The 2023…

Atea Share Savings Program – notification of trade

Reference is made to the stock exchange notice dated June 6, 2023 regarding the launch and terms of the Atea…

Mandatory notification of trade

On February 9, the following transactions took place in Atea ASA (the Company): 1. Exercise of stock options Employees of the Atea…

Presentation of 4[th] quarter 2023 results

Atea ASA will present its 4[th] quarter 2023 financial results on Thursday, 8 February 2024 at 08:00 CEST. The presentation will…

Ex dividend NOK 3.125 today

The shares in Atea ASA will be traded ex dividend NOK 3.125 as from today, 20 November 2023. For further information, please…

Key information relating to cash dividend to be paid by Atea ASA

The Board of Atea ASA has proposed a cash dividend with the following key details: Dividend amount:         …

Atea Share Savings Program – notification of trade

Reference is made to the stock exchange notice dated June 6, 2023 regarding the launch and terms of the Atea…

Mandatory notification of trade

On October 20, the following transactions took place in Atea ASA (the Company): 1. Exercise of stock options Employees of the Atea…

Presentation of 3[rd] quarter 2023 results

Atea ASA will present its 3[rd] quarter 2023 financial results on Thursday, 19 October 2023 at 08:00 CEST. The presentation will…

Atea Pharmaceuticals downgraded to underweight from neutral at J.P. Morgan

Um den gesamten Artikel unter marketwatch.com zu lesen, klicken Sie bitte auf die Überschrift...…

Atea Share Savings Program – notification of trade

Reference is made to the stock exchange notice dated June 6, 2023 regarding the launch and terms of the Atea…

Atea Pharmaceuticals GAAP EPS of -$0.34 beats by $0.15

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Form 10-Q Atea Pharmaceuticals, For: Jun 30

Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…

Correction - Mandatory notification of trade

With reference to stock announcement dated 18 July 2023. The number of shares acquired should be 140,000, and not 20,000…

Mandatory notification of trade

On July 18, 2023, Systemintegration ApS acquired 20,000 shares in Atea ASA at a price of NOK 136.83. Board member…

Atea Q2 2023 financial report and presentation

Atea reported strong revenue growth, higher operating profit and solid cash flow from operations in Q2 2023. · Strong…

Form 8-K Atea Pharmaceuticals, For: Jun 16

Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…

Atea earns platinum-level sustainability award for fourth consecutive year

For the fourth consecutive year, Atea ASA has earned the highest (“platinum”) rating in environmental and social performance by EcoVadis,…

Atea Share Savings Program – notification of trade

Atea ASA has established an Employee Share Savings Program (the “Program”), which is open to all employees of the Atea…

Atea Pharmaceuticals to Present at the Jefferies Healthcare Conference

BOSTON, June 05, 2023 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company engaged…

Atea rejects takeover offer from Tang Capital Partners

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Atea Pharmaceuticals Rejects Buyout Offer

Atea Pharmaceuticals Rejects Buyout Offer...…

Lordstown Motors, Atea Pharmaceuticals See Activist Investor Action

Lordstown Motors’ former CEO Steve burns lowered his stake in the maker of electric trucks. Atea Pharmaceuticals is evaluating an…

Atea Pharma Confirms Receipt of Unsolicited Proposal; Shares Rise

Atea Pharma Confirms Receipt of Unsolicited Proposal; Shares Rise...…

Atea Pharmaceuticals Up 35% on Buyout Proposal From Tang Capital

Atea Pharmaceuticals Up 35% on Buyout Proposal From Tang Capital...…

Atea Pharmaceuticals jumps on $5.75 a share takeover offer from Tang Capital

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Atea Pharmaceuticals GAAP EPS of -$0.43 beats by $0.07

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Loan agreement with European Investment Bank (EIB)

Reference is made to the stock exchange notice dated April 27, 2023 regarding a new loan agreement with the European…

New Chairman of Atea ASA

The Board of Directors of Atea ASA has elected Sven Madsen (b. 1964) to serve as Chairman of the Board. …

Atea Pharmaceuticals to Host First Quarter 2023 Financial Results Conference Call on May 8, 2023

BOSTON, May 01, 2023 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company engaged…

Mandatory notification of trade

On April 28, the following transactions took place in Atea ASA (the Company): 1. Exercise of stock options Employees of the Atea…

Ex dividend NOK 3.125 today

The shares in Atea ASA will be traded ex dividend NOK 3.125 as from today, 28 April 2023. For further information, please…

Annual General Meeting held in Atea ASA

The Annual General Meeting in Atea ASA was held on 27 April 2023. All issues were resolved in accordance with…

Loan agreement with European Investment Bank (EIB)

Atea ASA has entered into a new loan agreement for EUR 50,000,000 with the European Investment Bank. Atea will draw…

Atea Q1 2023 financial report and presentation

Atea reported another consecutive quarter of strong sales growth, record profits and solid cash flow from operations in Q1 2023. …

Atea Pharmaceuticals Announces U.S. FDA Fast Track Designation Granted to Bemnifosbuvir, an Investigational Oral Antiviral, for the Treatment of COVID-19

BOSTON, April 25, 2023 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company engaged…

Presentation of 1[st] quarter 2023 results

Atea ASA will present its 1[st] quarter 2023 financial results on Thursday, 27 April 2023 at 08:00 CEST. The presentation will…

Atea Announces Presentation of Bemnifosbuvir Data Demonstrating Reduced Hospitalizations for COVID-19 Patients at 2023 European Congress of Clinical Microbiology & Infectious Diseases

71% reduction in risk of hospitalization for mild to moderate COVID-19 outpatients treated with bemnifosbuvir versus placebo in MORNINGSKY study,…

Notice of Annual General Meeting

The Annual General Meeting will be held on Thursday 27 April 2023 at 09:30 a.m. at Thon Hotel Vika Atrium,…